Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial

The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile

Sai Life Sciences unveils 2024–25 sustainability report

The company also reported significant progress toward its internally defined Sustainable Development Goals

UK to get groundbreaking early detection test for bowel cancer

Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status

GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access

GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%

Granules receives FDA tentative approval for generic Amphetamine ER orally disintegrating tablets

Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia

GABIT acquires Swedish nutrition brand Nack to build integrated longevity ecosystem

BPL Medical Technologies funds AI dept at Sri S Ramasamy Naidu Memorial College

The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club

Gut health crisis fuelling anxiety, early ageing & lifestyle diseases

The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing

Takeda posts strong Phase 3 win for oral psoriasis drug

Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies

EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease

Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD